• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: pSivida’s Durasert lessens recurrence of uveitis through 12 months

May 9, 2017 By Sarah Faulkner

pSivida (NSDQ:PSDV) touted 1-year follow-up data yesterday for the company’s Durasert 3-year treatment of posterior segment uveitis. The data, which was presented at the Association for Research in Vision and Ophthalmology annual meeting, is from pSivida’s 1st phase III trial.

The data showed that the 3-year uveitis implant significantly reduced the recurrence of posterior segment uveitis through 12 months – 27.6% of patients treated with Durasert had a recurrence, compared to 85.7% of patients in the sham group. In phakic patients, 33.3% in the Durasert group required a cataract surgery in the year-long follow-up, versus 4.8% of patients in the sham group.

The best corrected visual acuity gain of 15 letters or more at 6 and 12 months was 23% and 22.4% for Durasert and 7.3% and 10.3% for the sham procedure.

Intraocular pressure elevation was 1.3mm for Durasert at 12 months and 0.2mm for sham, on average. About 26.4% of Durasert patients needed IOP-lowering therapy after 1 year, compared to 26.2% for their counterparts in the control group.

“The data presented today by Dr. Jaffe continues to reinforce pSivida’s proven technology and depth of our innovation,” president & CEO Nancy Lurker said in prepared remarks.  “The results, both at six and 12 months, demonstrated a significant reduction in the prevention of recurrence of posterior segment uveitis – a devastating disease and the third leading cause of blindness.  Our market research indicates strong interest in using the product driven by the results of our first Phase III clinical trial demonstrating a significant, and durable, reduction in recurrence rates, improvements in BCVA and a favorable tolerability profile at 12 months. We continue to expect the 1st read-out of our 2nd Phase III clinical trial of Durasert and submission of the European Market Authorization Application (MAA) by the end of June.  We remain on track to also file a New Drug Application (NDA) with the FDA in the calendar 4th quarter of 2017.”

PSDV shares were trading at $1.92 in afternoon activity, up 1.2%.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS